Guggenheim assumed coverage of Nuvalent (NUVL) with a Buy rating and price target of $122, up from $105.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NUVL:
- Nuvalent initiated with an Outperform at Raymond James
- Nuvalent initiated with an Overweight at Piper Sandler
- Nuvalent Reports Q2 2025 Financials and Pipeline Progress
- Nuvalent’s Promising Drug Pipeline and Strategic Trials Drive Buy Rating
- Nuvalent’s Promising Developments and Strong Financial Position Justify Buy Rating